WO2000018439A3 - Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren - Google Patents

Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren Download PDF

Info

Publication number
WO2000018439A3
WO2000018439A3 PCT/EP1999/007198 EP9907198W WO0018439A3 WO 2000018439 A3 WO2000018439 A3 WO 2000018439A3 EP 9907198 W EP9907198 W EP 9907198W WO 0018439 A3 WO0018439 A3 WO 0018439A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoangiogenesis
diagnosing
markers
therapy
treating tumours
Prior art date
Application number
PCT/EP1999/007198
Other languages
English (en)
French (fr)
Other versions
WO2000018439A2 (de
Inventor
Werner Krause
Peter Muschick
Original Assignee
Schering Ag
Werner Krause
Peter Muschick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Werner Krause, Peter Muschick filed Critical Schering Ag
Priority to AU12642/00A priority Critical patent/AU1264200A/en
Publication of WO2000018439A2 publication Critical patent/WO2000018439A2/de
Publication of WO2000018439A3 publication Critical patent/WO2000018439A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Die Erfindung betrifft die Verwendung von Konjugaten aus Neoangiogenese-Markern und Wirkgruppen zur Diagnose und/oder Therapie von Tumoren, sowie neue Neoangiogenese-Marker-Konjugate, diese Verbindungen enthaltende Mittel und Verfahren zu ihrer Herstellung.
PCT/EP1999/007198 1998-09-29 1999-09-29 Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren WO2000018439A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12642/00A AU1264200A (en) 1998-09-29 1999-09-29 Use of neoangiogenesis markers for diagnosing and treating tumours by therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845798A DE19845798A1 (de) 1998-09-29 1998-09-29 Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
DE19845798.7 1998-09-29

Publications (2)

Publication Number Publication Date
WO2000018439A2 WO2000018439A2 (de) 2000-04-06
WO2000018439A3 true WO2000018439A3 (de) 2000-09-14

Family

ID=7883448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007198 WO2000018439A2 (de) 1998-09-29 1999-09-29 Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren

Country Status (3)

Country Link
AU (1) AU1264200A (de)
DE (1) DE19845798A1 (de)
WO (1) WO2000018439A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
CA2377188A1 (en) * 1999-06-17 2000-12-28 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting tumor vasculature
EP1257268A2 (de) * 2000-02-14 2002-11-20 Novolytics Inc. Diagnostische und therapeutische zusammensetzungen sowie verfahren zur beeinflussung von tumorwachstum mit sauerstoff-mimetischen verbindungen
EP1296678A2 (de) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Arzneimittel mit vitronektin-rezeptor-antagonistischer wirkung zur anwendung in der kombinationstherapie
DE10104389A1 (de) * 2001-01-19 2002-08-01 Schering Ag Multimere Photosensibilisatoren sowie deren Konjugate für die PDT
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003080593A1 (fr) * 2002-03-22 2003-10-02 Beijing Jiankai Technology Co., Ltd. Conjugues hydrophiles de polymeres-flavonoides et compositions pharmaceutiques les contenant
DE10308870B4 (de) * 2003-02-28 2006-07-27 Austriamicrosystems Ag Bipolartransistor mit verbessertem Basis-Emitter-Übergang und Verfahren zur Herstellung
DE10356567A1 (de) * 2003-12-04 2005-07-07 Christian-Albrechts-Universität Zu Kiel Radiosensibilisatoren und Herstellungsverfahren
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
DK2574341T3 (en) 2004-03-29 2017-06-26 Univ South Florida Effective treatment of tumors and cancer with triciribin phosphate
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
WO2006022895A2 (en) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
CN102898391B (zh) * 2012-09-06 2014-10-01 中国工程物理研究院核物理与化学研究所 10-（羧甲基-氨基）-乙基-3-[三叔丁氧甲酰基-四氮杂环十二烷基]及制备方法
CN110354097B (zh) * 2019-07-19 2021-08-03 湖南大学 一种五氟尿嘧啶纳米药物制剂的制备方法及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004164A1 (en) * 1986-01-06 1987-07-16 The University Of Melbourne Technetium-antibody conjugate
WO1995012414A1 (en) * 1993-11-05 1995-05-11 Repligen Corporation Novel modified pf4 compositions and methods of use
WO1997019938A1 (es) * 1995-11-29 1997-06-05 Consejo Superior Investigaciones Cientificas Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones
EP0781778A1 (de) * 1995-12-29 1997-07-02 Pharmachemie B.V. Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie
WO1997031655A2 (en) * 1996-02-27 1997-09-04 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for therapeutic use
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO1999045951A2 (en) * 1998-03-11 1999-09-16 President And Fellows Of Harvard College Thy-1 expression in angiogenesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938505B1 (de) * 1996-05-31 2002-03-06 Health Research, Inc. Monoklonale Antikörper gegen Endoglin und ihre Verwendung in der anti-Angiogenese-Therapie
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004164A1 (en) * 1986-01-06 1987-07-16 The University Of Melbourne Technetium-antibody conjugate
WO1995012414A1 (en) * 1993-11-05 1995-05-11 Repligen Corporation Novel modified pf4 compositions and methods of use
WO1997019938A1 (es) * 1995-11-29 1997-06-05 Consejo Superior Investigaciones Cientificas Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones
EP0781778A1 (de) * 1995-12-29 1997-07-02 Pharmachemie B.V. Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie
WO1997031655A2 (en) * 1996-02-27 1997-09-04 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for therapeutic use
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO1999045951A2 (en) * 1998-03-11 1999-09-16 President And Fellows Of Harvard College Thy-1 expression in angiogenesis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AL-YAHYAEE S A S ET AL: "CELL TARGETING OF A PORE-FORMING TOXIN, CYTA BETA-ENDOTOXIN FROM BACILLUS THURINGIENSIS SUBSPECIES ISRAELENSIS, BY CONJUGATING CYTA WITH ANTI-THY 1 MONOCLONAL ANTIBODIES AND INSULIN", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 4, 1 July 1996 (1996-07-01), pages 451 - 460, XP000637463, ISSN: 1043-1802 *
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 *
LEE W S ET AL: "Thy - 1, a novel marker for angiogenesis upregulated by inflammatory cytokines [see comments]", CIRCULATION RESEARCH,US,GRUNE AND STRATTON, BALTIMORE, vol. 82, no. 8, 4 May 1998 (1998-05-04), pages 845 - 851, XP002119748, ISSN: 0009-7330 *
NERI D ET AL: "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform", NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 15, no. 12, November 1997 (1997-11-01), pages 1271 - 1275, XP002124779, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
AU1264200A (en) 2000-04-17
WO2000018439A2 (de) 2000-04-06
DE19845798A1 (de) 2000-04-13

Similar Documents

Publication Publication Date Title
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
WO2001091805A3 (en) Compounds for targeting endothelial cells
WO1999054326A8 (de) Dihydropyrimidine
MX9701497A (es) Polimeros de ioneno que contienen aniones biologicamente activos.
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
DE69429524T2 (de) Aminocyclohexylester und ihre anwendung
AU6613896A (en) Chemical compounds
IL129592A0 (en) 5-HT1f agonists
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2002004455A3 (en) 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
HK1076812A1 (en) Cyanoguanidine prodrugs
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
HK1067545A1 (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
CA2153778A1 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IL135634A0 (en) 5-htif agonists
WO2000040752A3 (en) Cancer associated genes and their products
WO2005016958A3 (en) Compounds for treating tumors
WO1998048844A3 (de) Ionenpaare, verfahren zu ihrer herstellung und ihre verwendung als kontrastmittel
WO2002038803A3 (de) Neue marker für die diagnose und therapie von tumoren
WO2003020221A3 (en) Method of treating cancerous disease
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
ZA200005575B (en) Preparation of an aqueous composition for treating leather.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12642

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE ES GD GE GH GM HR HU ID IL IN IS JP KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE ES GD GE GH GM HR HU ID IL IN IS JP KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

NENP Non-entry into the national phase

Ref country code: CA